Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TVRD
- Price
- 4.83
- Stock movement up
- +0.13 (2.77%)
- Company name
- Tvardi Therapeutics, Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 45.21M
- Ent value
- 34.95M
- Price/Sales
- 11.24
- Price/Book
- 1.62
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TVRD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.24 |
| Price to Book | 1.62 |
| EV to Sales | 8.69 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 9.36M |
| EPS (TTM) | -1.49 |
| FCF per share (TTM) | -2.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.02M |
| Gross profit (TTM) | 3.94M |
| Operating income (TTM) | -23.19M |
| Net income (TTM) | -13.95M |
| EPS (TTM) | -1.49 |
| EPS (1y forward) | -2.96 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 97.79% |
| Operating margin (TTM) | -576.39% |
| Profit margin (TTM) | -346.55% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 21.42M |
| Net receivables | 0.00 |
| Total current assets | 38.44M |
| Goodwill | 0.00 |
| Intangible assets | 338.00K |
| Property, plant and equipment | 223.00K |
| Total assets | 39.02M |
| Accounts payable | 4.08M |
| Short/Current long term debt | 228.00K |
| Total current liabilities | 11.04M |
| Total liabilities | 11.15M |
| Shareholder's equity | 27.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.86M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -21.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -50.04% |
| Return on Assets | -35.74% |
| Return on Invested Capital | -49.84% |
| Cash Return on Invested Capital | -78.12% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.69 |
| Daily high | 4.89 |
| Daily low | 4.69 |
| Daily Volume | 38K |
| All-time high | 42.98 |
| 1y analyst estimate | 56.20 |
| Beta | - |
| EPS (TTM) | -1.49 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Mar 2026 |
Downside potential
Loading...
Downside potential data
| TVRD | S&P500 | |
| Current price drop from All-time high | -88.76% | -0.89% |
| Highest price drop | -91.28% | -19.00% |
| Date of highest drop | 2 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -74.78% | -2.49% |
| Avg time to new high | 14 days | 6 days |
| Max time to new high | 72 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
45.21M
Marketcap category
Small-cap
Description
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Employees
12
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page